ZLD Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Zelira Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.75 |
| 52 Week High | AU$1.10 |
| 52 Week Low | AU$0.28 |
| Beta | 0.83 |
| 11 Month Change | 1.35% |
| 3 Month Change | 102.70% |
| 1 Year Change | -23.86% |
| 33 Year Change | -90.03% |
| 5 Year Change | -94.29% |
| Change since IPO | -81.37% |
Recent News & Updates
Recent updates
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 08
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?
Jul 14Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely
Jan 19Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Sep 25Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?
Jun 03A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation
Dec 31
Shareholder Returns
| ZLD | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 11.9% | 0.3% | 1.5% |
| 1Y | -23.9% | 79.1% | 15.2% |
Return vs Industry: ZLD underperformed the Australian Pharmaceuticals industry which returned 79.1% over the past year.
Return vs Market: ZLD underperformed the Australian Market which returned 15.2% over the past year.
Price Volatility
| ZLD volatility | |
|---|---|
| ZLD Average Weekly Movement | 23.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: ZLD's share price has been volatile over the past 3 months.
Volatility Over Time: ZLD's weekly volatility has increased from 14% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oludare Odumosu | zeliratx.com |
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
Zelira Therapeutics Limited Fundamentals Summary
| ZLD fundamental statistics | |
|---|---|
| Market cap | AU$8.51m |
| Earnings (TTM) | -AU$36.57m |
| Revenue (TTM) | AU$94.95k |
89.6x
P/S Ratio-0.2x
P/E RatioIs ZLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZLD income statement (TTM) | |
|---|---|
| Revenue | AU$94.95k |
| Cost of Revenue | AU$328.89k |
| Gross Profit | -AU$233.93k |
| Other Expenses | AU$36.33m |
| Earnings | -AU$36.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | -246.37% |
| Net Profit Margin | -38,513.04% |
| Debt/Equity Ratio | -135.5% |
How did ZLD perform over the long term?
See historical performance and comparison